ATE290089T1 - Methode zur verstärkung der biologischen aktivität von liganden - Google Patents

Methode zur verstärkung der biologischen aktivität von liganden

Info

Publication number
ATE290089T1
ATE290089T1 AT99968956T AT99968956T ATE290089T1 AT E290089 T1 ATE290089 T1 AT E290089T1 AT 99968956 T AT99968956 T AT 99968956T AT 99968956 T AT99968956 T AT 99968956T AT E290089 T1 ATE290089 T1 AT E290089T1
Authority
AT
Austria
Prior art keywords
polypeptide ligands
fusion polypeptide
ligands
enhancing
biological activity
Prior art date
Application number
AT99968956T
Other languages
English (en)
Inventor
Samuel J Davis
Nicholas W Gale
George D Yancopoulos
Neil Stahl
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE290089T1 publication Critical patent/ATE290089T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99968956T 1998-12-23 1999-12-23 Methode zur verstärkung der biologischen aktivität von liganden ATE290089T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11338798P 1998-12-23 1998-12-23
PCT/US1999/030900 WO2000037642A1 (en) 1998-12-23 1999-12-23 Method of enhancing the biological activity of ligands

Publications (1)

Publication Number Publication Date
ATE290089T1 true ATE290089T1 (de) 2005-03-15

Family

ID=22349103

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99968956T ATE290089T1 (de) 1998-12-23 1999-12-23 Methode zur verstärkung der biologischen aktivität von liganden

Country Status (12)

Country Link
US (1) US7008781B1 (de)
EP (1) EP1141294B1 (de)
JP (1) JP4493854B2 (de)
AT (1) ATE290089T1 (de)
AU (1) AU776393B2 (de)
CA (1) CA2354846A1 (de)
DE (1) DE69924009T2 (de)
HK (1) HK1040093B (de)
IL (1) IL143558A0 (de)
NZ (1) NZ512326A (de)
PL (1) PL199645B1 (de)
WO (1) WO2000037642A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901428D0 (sv) * 1999-04-21 1999-04-21 Karolinska Innovations Ab Amphibodies
AU2337801A (en) * 1999-12-23 2001-07-09 An-Go-Gen Inc. Angiopoietin analogs
EP2163642A1 (de) 2000-08-08 2010-03-17 M.G.V.S. Ltd. Nukleinsäurekonstrukte, damit transformierte vaskuläre Zellen, pharmezeutische Zusammensetzungen und Verfahren zur Induktion der Angiogenese
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US7052695B2 (en) 2001-10-25 2006-05-30 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of treating hypertension
GB0201679D0 (en) * 2002-01-25 2002-03-13 Asterion Ltd Polypeptide variants
US7081443B2 (en) * 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
EP2061489A4 (de) * 2006-09-15 2009-12-23 Burnham Inst Hochaffine ephb-rezeptorbindende verbindungen und anwendungsverfahren dafür
CA2693383C (en) 2006-10-27 2017-03-28 Sunnybrook Health Sciences Center Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
EP2671891A3 (de) 2008-06-27 2014-03-05 Amgen Inc. Ang-2-Hemmung zur Behandlung von Multipler Sklerose
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
EA201890895A1 (ru) 2013-03-15 2019-02-28 Зинджения, Инк. Мультивалентные и моновалентные мультиспецифические комплексы и их применение
WO2014165963A1 (en) 2013-04-11 2014-10-16 Sunnybrook Research Institute Methods, uses and compositions of tie2 agonists
MX2016005446A (es) 2013-11-01 2017-01-05 Regeneron Pharma Intervenciones a base de angiopoyetina para tratar la malaria cerebral.
US10588940B2 (en) 2015-11-06 2020-03-17 Regeneron Pharmaceuticals, Inc. Use of angiopoietins in promoting blood coagulation and in the treatment of blood coagulation disorders
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090105A1 (en) * 1990-08-29 1992-03-01 Jean-Paul Soulillou Protein polyligands joined to a stable protein core
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
AU685765B2 (en) 1992-11-13 1998-01-29 Amgen, Inc. (Eck) receptor ligands
US5747033A (en) 1993-10-28 1998-05-05 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of Eph family ligands
US5879672A (en) 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
CA2187167A1 (en) 1994-04-04 1995-10-12 Samuel Davis Biologically active eph family ligands
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5650490A (en) 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
CA2216963C (en) 1995-04-06 2010-06-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligands, methods of making and uses thereof
CA2222055A1 (en) * 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
ATE314470T1 (de) 1995-10-25 2006-01-15 Regeneron Pharma Biologisch aktive liganden der eph familie
ATE319827T1 (de) * 1995-11-17 2006-03-15 Asahi Chemical Ind Polypeptid, das die differenzierung unterdrueckt
US5814478A (en) 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
CA2213512A1 (en) 1995-12-22 1997-07-03 Toray Industries, Inc. Method for producing bioactive fusion protein
US5851797A (en) 1996-06-19 1998-12-22 Regeneron Pharmaceuticals, Inc. Tie ligand-3, methods of making and uses thereof
ES2194203T3 (es) 1996-06-19 2003-11-16 Regeneron Pharma Ligando del receptor tie-2 (ligando-4 de tie) y su uso.
US6265564B1 (en) 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule

Also Published As

Publication number Publication date
AU2714700A (en) 2000-07-12
WO2000037642A9 (en) 2000-11-02
PL199645B1 (pl) 2008-10-31
EP1141294A1 (de) 2001-10-10
DE69924009T2 (de) 2006-04-13
WO2000037642A1 (en) 2000-06-29
CA2354846A1 (en) 2000-06-29
NZ512326A (en) 2003-11-28
US7008781B1 (en) 2006-03-07
JP4493854B2 (ja) 2010-06-30
DE69924009D1 (de) 2005-04-07
PL349158A1 (en) 2002-07-01
AU776393B2 (en) 2004-09-09
JP2003506008A (ja) 2003-02-18
HK1040093A1 (en) 2002-05-24
EP1141294B1 (de) 2005-03-02
HK1040093B (zh) 2005-05-06
IL143558A0 (en) 2002-04-21

Similar Documents

Publication Publication Date Title
ATE290089T1 (de) Methode zur verstärkung der biologischen aktivität von liganden
ATE212059T1 (de) Methoden zur identifizierung heterofunktionaler fusionsproteine
DK1015587T3 (da) DcR3 polypeptid, en TNFR-homolog
DE3280479T2 (de) Rekombinante DNS-Mittel und Verfahren
RU2007142191A (ru) Варианты бета-цепи hgf
DE69534588D1 (de) Protocadherin-proteine und verwendungen davon
IL130403A (en) Oil bodies and associated proteins as affinity matrices
ATE135371T1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
DK1095140T3 (da) Neurotrofe faktorer
ATE139784T1 (de) Hybrid-rezeptoren, diese kodierende nukleinsäure, ihre herstellung und ihre verwendung zur bestimmung von liganden sowie deren antagonisten oder agonisten
DE69941701D1 (de) Mutanten von flt3-l und ihre verwendungen
TR200001861T2 (tr) Yeni G protein birleştirilmiş alıcı
DE69534551D1 (de) Neue methode zum auffindenund bewerten biologisch aktiver moleküle
SE8801701D0 (sv) Production technology based on enzymic method
PT1200561E (pt) Clone celular recombinante estavel, sua producao e utilizacao
ATE360695T1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
ES2192199T3 (es) Ligandos de la familia eph biologicamente activos.
DE69935782D1 (de) Brustkrebsresistenzprotein (bcrp) und für dieses kodierende dna
ATE443761T1 (de) Rtd receptor
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
ATE348171T1 (de) Proteine mit lecithin-cholesterin acetyltransferase-ähnlicher aktivität, deren herstellung und verwendung
DE68917154D1 (de) C-terminus-amidierungsenzym-zusammensetzung, verfahren zur herstellung und verwendung.
EA200000270A1 (ru) КОМПОЗИЦИИ ДЛЯ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ СЕКРЕТИРУЕМЫЕ БЕЛКИ, ТАКИЕ КАК β-ИНТЕРФЕРОН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
EP1331265A3 (de) Durch Zelldichte stimulierte Protein-Tyrosin-Phosphatasen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1141294

Country of ref document: EP